- Home
- LOT vs LGND Comparison
LOT vs LGND Comparison
Compare LOT & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOT
- LGND
- Stock Information
- Founded
- LOT 1948
- LGND 1987
- Country
- LOT China
- LGND United States
- Employees
- LOT N/A
- LGND N/A
- Industry
- LOT
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- LOT
- LGND Health Care
- Exchange
- LOT NYSE
- LGND Nasdaq
- Market Cap
- LOT 2.0B
- LGND 2.2B
- IPO Year
- LOT N/A
- LGND 1992
- Fundamental
- Price
- LOT $2.57
- LGND $120.67
- Analyst Decision
- LOT
- LGND Strong Buy
- Analyst Count
- LOT 0
- LGND 6
- Target Price
- LOT N/A
- LGND $145.00
- AVG Volume (30 Days)
- LOT 145.0K
- LGND 81.8K
- Earning Date
- LOT 04-07-2025
- LGND 02-27-2025
- Dividend Yield
- LOT N/A
- LGND N/A
- EPS Growth
- LOT N/A
- LGND 160.46
- EPS
- LOT N/A
- LGND 2.47
- Revenue
- LOT $1,013,890,000.00
- LGND $152,422,000.00
- Revenue This Year
- LOT $41.67
- LGND $26.86
- Revenue Next Year
- LOT $65.29
- LGND $14.95
- P/E Ratio
- LOT N/A
- LGND $48.82
- Revenue Growth
- LOT 213.08
- LGND N/A
- 52 Week Low
- LOT $2.21
- LGND $67.72
- 52 Week High
- LOT $17.99
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- LOT 42.12
- LGND 59.36
- Support Level
- LOT $2.21
- LGND $110.42
- Resistance Level
- LOT $3.57
- LGND $119.26
- Average True Range (ATR)
- LOT 0.27
- LGND 3.82
- MACD
- LOT 0.04
- LGND 0.61
- Stochastic Oscillator
- LOT 26.47
- LGND 81.35
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.